The Italian Questionnaire for Cancer Breakthrough Pain Diagnosis, a Multicenter Validation Study

Introduction The literature lacks formally validated and reliable tools for the diagnosis of breakthrough cancer pain (BTcP). The Italian Questionnaire for BTcP diagnosis (IQ-BTP) is an 11-item questionnaire aimed at detecting potential-BTP and classifying it into three likelihood classes: high, int...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Pain and Therapy 2021-12, Vol.10 (2), p.1171-1188
Hauptverfasser: Samolsky Dekel, Boaz Gedaliahu, Gori, Alberto, Gunnellini, Marco, Gioia, Angela, Di Marco, Mariacristina, Casale, Giuseppe, Bevilacqua, Marzio, Bersani, Pietro, Melotti, Rita Maria
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 1188
container_issue 2
container_start_page 1171
container_title Pain and Therapy
container_volume 10
creator Samolsky Dekel, Boaz Gedaliahu
Gori, Alberto
Gunnellini, Marco
Gioia, Angela
Di Marco, Mariacristina
Casale, Giuseppe
Bevilacqua, Marzio
Bersani, Pietro
Melotti, Rita Maria
description Introduction The literature lacks formally validated and reliable tools for the diagnosis of breakthrough cancer pain (BTcP). The Italian Questionnaire for BTcP diagnosis (IQ-BTP) is an 11-item questionnaire aimed at detecting potential-BTP and classifying it into three likelihood classes: high, intermediate, and low. Methods A multicenter, prospective, and observational study was designed to validate the IQ-BTP. In three consecutive visits with each cancer patient, the demographic and clinical details of the patient, the Brief Pain Inventory (BPI) scores, IQ-BTP outcomes, and clinicians' autonomous BTcP diagnosis (gold standard) and the agreement of this diagnosis with IQ-BTP outcomes were recorded. The assessed domains for IQ-BTP validation were: Validity, including content and face validity, construct validity (hypothesis testing, and cross‐cultural validity\measurement invariance), and criterion validity; Reliability (internal consistency, reliability, and measurement error); Interpretability, and Responsiveness. Results Seven palliative and pain management facilities in Italy recruited 280 patients, yielding 753 evaluations. Using the IQ-BTP, the rate of potential-BTcP was 27.2%, of which its likely presence was high in 52.7% of patients, intermediate in 38.5, and low in 8.8%. The BPI item scores differed significantly between the two IQ-BTP classes (no-BTcP and potential-BTcP classes). The correlation of the latter class with BPI items was significant but low. The IQ-BTcP showed two principal components, accounting for 66.6% of the variance. Cronbach’s α was 0.71. The agreement rate between the gold standard and IQ-BTP outcomes was 82%. Cohen's κ was 0.535. The IQ-BTP showed sensitivity and specificity of 69 and 86%, respectively. Conclusions The IQ-BTP extensive formal validation showed satisfactory psychometric and validity properties. Its content, face, construct, and criterion validities and its reliability, interpretability, and responsiveness were shown. Its use enabled potential-BTcP to be identified and differentiated into three likelihood classes with direct therapeutic and epidemiological implications. The latter may be confirmed in future studies.
doi_str_mv 10.1007/s40122-021-00274-9
format Article
fullrecord <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8586321</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A682168763</galeid><sourcerecordid>A682168763</sourcerecordid><originalsourceid>FETCH-LOGICAL-c513t-deff5273e99532067151773ed66d75f3e78c81f0f7f2a8a3a67871fefab1df013</originalsourceid><addsrcrecordid>eNp9kUtv1TAQhS0EolXpH2CBvGRBih9x7GyQyuVVqQgQBbEz02Sc65Jrt3aC1H-PQy4VbJAXfsw5n8ZzCHnM2QlnTD_PNeNCVEzwijGh66q9Rw4Fb2XVKP7t_v5shNQH5DjnK8aK3qi2Vg_JgaxZyw3Xh-T7xRbp2QSjh0A_zZgnH0MAn5C6mOgGQoeJvkwIP6ZtivOwpR_BB_rKwxBi9vkZBfp-HiffYZiK9GtB9bBQ6Odp7m8fkQcOxozH-_2IfHnz-mLzrjr_8PZsc3pedYrLqerROSW0xLZVUrBGc8V1ufZN02vlJGrTGe6Y006AAQmNNpo7dHDJe8e4PCIvVu71fLnDfukmwWivk99BurURvP23EvzWDvGnNco0UiyAp3tAijfLIOzO5w7HEQLGOVuhpGG1VlIV6ckqHWBE64OLhdiV1ePOdzGg8-X9tDGCN0Y3shjEauhSzDmhu-uLM7vEadc4bYnT_o7TtsX05O8f3Vn-hFcEchXkUgoDJnsV5xTKlP-H_QU4DawA</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2538047535</pqid></control><display><type>article</type><title>The Italian Questionnaire for Cancer Breakthrough Pain Diagnosis, a Multicenter Validation Study</title><source>DOAJ Directory of Open Access Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><source>Springer Nature OA Free Journals</source><creator>Samolsky Dekel, Boaz Gedaliahu ; Gori, Alberto ; Gunnellini, Marco ; Gioia, Angela ; Di Marco, Mariacristina ; Casale, Giuseppe ; Bevilacqua, Marzio ; Bersani, Pietro ; Melotti, Rita Maria</creator><creatorcontrib>Samolsky Dekel, Boaz Gedaliahu ; Gori, Alberto ; Gunnellini, Marco ; Gioia, Angela ; Di Marco, Mariacristina ; Casale, Giuseppe ; Bevilacqua, Marzio ; Bersani, Pietro ; Melotti, Rita Maria</creatorcontrib><description>Introduction The literature lacks formally validated and reliable tools for the diagnosis of breakthrough cancer pain (BTcP). The Italian Questionnaire for BTcP diagnosis (IQ-BTP) is an 11-item questionnaire aimed at detecting potential-BTP and classifying it into three likelihood classes: high, intermediate, and low. Methods A multicenter, prospective, and observational study was designed to validate the IQ-BTP. In three consecutive visits with each cancer patient, the demographic and clinical details of the patient, the Brief Pain Inventory (BPI) scores, IQ-BTP outcomes, and clinicians' autonomous BTcP diagnosis (gold standard) and the agreement of this diagnosis with IQ-BTP outcomes were recorded. The assessed domains for IQ-BTP validation were: Validity, including content and face validity, construct validity (hypothesis testing, and cross‐cultural validity\measurement invariance), and criterion validity; Reliability (internal consistency, reliability, and measurement error); Interpretability, and Responsiveness. Results Seven palliative and pain management facilities in Italy recruited 280 patients, yielding 753 evaluations. Using the IQ-BTP, the rate of potential-BTcP was 27.2%, of which its likely presence was high in 52.7% of patients, intermediate in 38.5, and low in 8.8%. The BPI item scores differed significantly between the two IQ-BTP classes (no-BTcP and potential-BTcP classes). The correlation of the latter class with BPI items was significant but low. The IQ-BTcP showed two principal components, accounting for 66.6% of the variance. Cronbach’s α was 0.71. The agreement rate between the gold standard and IQ-BTP outcomes was 82%. Cohen's κ was 0.535. The IQ-BTP showed sensitivity and specificity of 69 and 86%, respectively. Conclusions The IQ-BTP extensive formal validation showed satisfactory psychometric and validity properties. Its content, face, construct, and criterion validities and its reliability, interpretability, and responsiveness were shown. Its use enabled potential-BTcP to be identified and differentiated into three likelihood classes with direct therapeutic and epidemiological implications. The latter may be confirmed in future studies.</description><identifier>ISSN: 2193-8237</identifier><identifier>EISSN: 2193-651X</identifier><identifier>DOI: 10.1007/s40122-021-00274-9</identifier><identifier>PMID: 34091817</identifier><language>eng</language><publisher>Cheshire: Springer Healthcare</publisher><subject>Cancer pain ; Cancer patients ; Diagnosis ; Evaluation ; Health surveys ; Internal Medicine ; Medicine ; Medicine &amp; Public Health ; Original Research ; Pain Medicine ; Surveys</subject><ispartof>Pain and Therapy, 2021-12, Vol.10 (2), p.1171-1188</ispartof><rights>The Author(s) 2021</rights><rights>2021. The Author(s).</rights><rights>COPYRIGHT 2021 Springer</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c513t-deff5273e99532067151773ed66d75f3e78c81f0f7f2a8a3a67871fefab1df013</citedby><cites>FETCH-LOGICAL-c513t-deff5273e99532067151773ed66d75f3e78c81f0f7f2a8a3a67871fefab1df013</cites><orcidid>0000-0002-6458-3562 ; 0000-0002-5583-4892 ; 0000-0002-8392-385X ; 0000-0002-3470-9494 ; 0000-0002-9954-4117 ; 0000-0001-5932-9212 ; 0000-0001-6461-1466 ; 0000-0001-6258-6607 ; 0000-0002-9154-5860</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8586321/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8586321/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,860,881,27901,27902,41096,42165,51551,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34091817$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Samolsky Dekel, Boaz Gedaliahu</creatorcontrib><creatorcontrib>Gori, Alberto</creatorcontrib><creatorcontrib>Gunnellini, Marco</creatorcontrib><creatorcontrib>Gioia, Angela</creatorcontrib><creatorcontrib>Di Marco, Mariacristina</creatorcontrib><creatorcontrib>Casale, Giuseppe</creatorcontrib><creatorcontrib>Bevilacqua, Marzio</creatorcontrib><creatorcontrib>Bersani, Pietro</creatorcontrib><creatorcontrib>Melotti, Rita Maria</creatorcontrib><title>The Italian Questionnaire for Cancer Breakthrough Pain Diagnosis, a Multicenter Validation Study</title><title>Pain and Therapy</title><addtitle>Pain Ther</addtitle><addtitle>Pain Ther</addtitle><description>Introduction The literature lacks formally validated and reliable tools for the diagnosis of breakthrough cancer pain (BTcP). The Italian Questionnaire for BTcP diagnosis (IQ-BTP) is an 11-item questionnaire aimed at detecting potential-BTP and classifying it into three likelihood classes: high, intermediate, and low. Methods A multicenter, prospective, and observational study was designed to validate the IQ-BTP. In three consecutive visits with each cancer patient, the demographic and clinical details of the patient, the Brief Pain Inventory (BPI) scores, IQ-BTP outcomes, and clinicians' autonomous BTcP diagnosis (gold standard) and the agreement of this diagnosis with IQ-BTP outcomes were recorded. The assessed domains for IQ-BTP validation were: Validity, including content and face validity, construct validity (hypothesis testing, and cross‐cultural validity\measurement invariance), and criterion validity; Reliability (internal consistency, reliability, and measurement error); Interpretability, and Responsiveness. Results Seven palliative and pain management facilities in Italy recruited 280 patients, yielding 753 evaluations. Using the IQ-BTP, the rate of potential-BTcP was 27.2%, of which its likely presence was high in 52.7% of patients, intermediate in 38.5, and low in 8.8%. The BPI item scores differed significantly between the two IQ-BTP classes (no-BTcP and potential-BTcP classes). The correlation of the latter class with BPI items was significant but low. The IQ-BTcP showed two principal components, accounting for 66.6% of the variance. Cronbach’s α was 0.71. The agreement rate between the gold standard and IQ-BTP outcomes was 82%. Cohen's κ was 0.535. The IQ-BTP showed sensitivity and specificity of 69 and 86%, respectively. Conclusions The IQ-BTP extensive formal validation showed satisfactory psychometric and validity properties. Its content, face, construct, and criterion validities and its reliability, interpretability, and responsiveness were shown. Its use enabled potential-BTcP to be identified and differentiated into three likelihood classes with direct therapeutic and epidemiological implications. The latter may be confirmed in future studies.</description><subject>Cancer pain</subject><subject>Cancer patients</subject><subject>Diagnosis</subject><subject>Evaluation</subject><subject>Health surveys</subject><subject>Internal Medicine</subject><subject>Medicine</subject><subject>Medicine &amp; Public Health</subject><subject>Original Research</subject><subject>Pain Medicine</subject><subject>Surveys</subject><issn>2193-8237</issn><issn>2193-651X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>C6C</sourceid><recordid>eNp9kUtv1TAQhS0EolXpH2CBvGRBih9x7GyQyuVVqQgQBbEz02Sc65Jrt3aC1H-PQy4VbJAXfsw5n8ZzCHnM2QlnTD_PNeNCVEzwijGh66q9Rw4Fb2XVKP7t_v5shNQH5DjnK8aK3qi2Vg_JgaxZyw3Xh-T7xRbp2QSjh0A_zZgnH0MAn5C6mOgGQoeJvkwIP6ZtivOwpR_BB_rKwxBi9vkZBfp-HiffYZiK9GtB9bBQ6Odp7m8fkQcOxozH-_2IfHnz-mLzrjr_8PZsc3pedYrLqerROSW0xLZVUrBGc8V1ufZN02vlJGrTGe6Y006AAQmNNpo7dHDJe8e4PCIvVu71fLnDfukmwWivk99BurURvP23EvzWDvGnNco0UiyAp3tAijfLIOzO5w7HEQLGOVuhpGG1VlIV6ckqHWBE64OLhdiV1ePOdzGg8-X9tDGCN0Y3shjEauhSzDmhu-uLM7vEadc4bYnT_o7TtsX05O8f3Vn-hFcEchXkUgoDJnsV5xTKlP-H_QU4DawA</recordid><startdate>20211201</startdate><enddate>20211201</enddate><creator>Samolsky Dekel, Boaz Gedaliahu</creator><creator>Gori, Alberto</creator><creator>Gunnellini, Marco</creator><creator>Gioia, Angela</creator><creator>Di Marco, Mariacristina</creator><creator>Casale, Giuseppe</creator><creator>Bevilacqua, Marzio</creator><creator>Bersani, Pietro</creator><creator>Melotti, Rita Maria</creator><general>Springer Healthcare</general><general>Springer</general><scope>C6C</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>IAO</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-6458-3562</orcidid><orcidid>https://orcid.org/0000-0002-5583-4892</orcidid><orcidid>https://orcid.org/0000-0002-8392-385X</orcidid><orcidid>https://orcid.org/0000-0002-3470-9494</orcidid><orcidid>https://orcid.org/0000-0002-9954-4117</orcidid><orcidid>https://orcid.org/0000-0001-5932-9212</orcidid><orcidid>https://orcid.org/0000-0001-6461-1466</orcidid><orcidid>https://orcid.org/0000-0001-6258-6607</orcidid><orcidid>https://orcid.org/0000-0002-9154-5860</orcidid></search><sort><creationdate>20211201</creationdate><title>The Italian Questionnaire for Cancer Breakthrough Pain Diagnosis, a Multicenter Validation Study</title><author>Samolsky Dekel, Boaz Gedaliahu ; Gori, Alberto ; Gunnellini, Marco ; Gioia, Angela ; Di Marco, Mariacristina ; Casale, Giuseppe ; Bevilacqua, Marzio ; Bersani, Pietro ; Melotti, Rita Maria</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c513t-deff5273e99532067151773ed66d75f3e78c81f0f7f2a8a3a67871fefab1df013</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Cancer pain</topic><topic>Cancer patients</topic><topic>Diagnosis</topic><topic>Evaluation</topic><topic>Health surveys</topic><topic>Internal Medicine</topic><topic>Medicine</topic><topic>Medicine &amp; Public Health</topic><topic>Original Research</topic><topic>Pain Medicine</topic><topic>Surveys</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Samolsky Dekel, Boaz Gedaliahu</creatorcontrib><creatorcontrib>Gori, Alberto</creatorcontrib><creatorcontrib>Gunnellini, Marco</creatorcontrib><creatorcontrib>Gioia, Angela</creatorcontrib><creatorcontrib>Di Marco, Mariacristina</creatorcontrib><creatorcontrib>Casale, Giuseppe</creatorcontrib><creatorcontrib>Bevilacqua, Marzio</creatorcontrib><creatorcontrib>Bersani, Pietro</creatorcontrib><creatorcontrib>Melotti, Rita Maria</creatorcontrib><collection>Springer Nature OA Free Journals</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Gale Academic OneFile</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Pain and Therapy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Samolsky Dekel, Boaz Gedaliahu</au><au>Gori, Alberto</au><au>Gunnellini, Marco</au><au>Gioia, Angela</au><au>Di Marco, Mariacristina</au><au>Casale, Giuseppe</au><au>Bevilacqua, Marzio</au><au>Bersani, Pietro</au><au>Melotti, Rita Maria</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The Italian Questionnaire for Cancer Breakthrough Pain Diagnosis, a Multicenter Validation Study</atitle><jtitle>Pain and Therapy</jtitle><stitle>Pain Ther</stitle><addtitle>Pain Ther</addtitle><date>2021-12-01</date><risdate>2021</risdate><volume>10</volume><issue>2</issue><spage>1171</spage><epage>1188</epage><pages>1171-1188</pages><issn>2193-8237</issn><eissn>2193-651X</eissn><abstract>Introduction The literature lacks formally validated and reliable tools for the diagnosis of breakthrough cancer pain (BTcP). The Italian Questionnaire for BTcP diagnosis (IQ-BTP) is an 11-item questionnaire aimed at detecting potential-BTP and classifying it into three likelihood classes: high, intermediate, and low. Methods A multicenter, prospective, and observational study was designed to validate the IQ-BTP. In three consecutive visits with each cancer patient, the demographic and clinical details of the patient, the Brief Pain Inventory (BPI) scores, IQ-BTP outcomes, and clinicians' autonomous BTcP diagnosis (gold standard) and the agreement of this diagnosis with IQ-BTP outcomes were recorded. The assessed domains for IQ-BTP validation were: Validity, including content and face validity, construct validity (hypothesis testing, and cross‐cultural validity\measurement invariance), and criterion validity; Reliability (internal consistency, reliability, and measurement error); Interpretability, and Responsiveness. Results Seven palliative and pain management facilities in Italy recruited 280 patients, yielding 753 evaluations. Using the IQ-BTP, the rate of potential-BTcP was 27.2%, of which its likely presence was high in 52.7% of patients, intermediate in 38.5, and low in 8.8%. The BPI item scores differed significantly between the two IQ-BTP classes (no-BTcP and potential-BTcP classes). The correlation of the latter class with BPI items was significant but low. The IQ-BTcP showed two principal components, accounting for 66.6% of the variance. Cronbach’s α was 0.71. The agreement rate between the gold standard and IQ-BTP outcomes was 82%. Cohen's κ was 0.535. The IQ-BTP showed sensitivity and specificity of 69 and 86%, respectively. Conclusions The IQ-BTP extensive formal validation showed satisfactory psychometric and validity properties. Its content, face, construct, and criterion validities and its reliability, interpretability, and responsiveness were shown. Its use enabled potential-BTcP to be identified and differentiated into three likelihood classes with direct therapeutic and epidemiological implications. The latter may be confirmed in future studies.</abstract><cop>Cheshire</cop><pub>Springer Healthcare</pub><pmid>34091817</pmid><doi>10.1007/s40122-021-00274-9</doi><tpages>18</tpages><orcidid>https://orcid.org/0000-0002-6458-3562</orcidid><orcidid>https://orcid.org/0000-0002-5583-4892</orcidid><orcidid>https://orcid.org/0000-0002-8392-385X</orcidid><orcidid>https://orcid.org/0000-0002-3470-9494</orcidid><orcidid>https://orcid.org/0000-0002-9954-4117</orcidid><orcidid>https://orcid.org/0000-0001-5932-9212</orcidid><orcidid>https://orcid.org/0000-0001-6461-1466</orcidid><orcidid>https://orcid.org/0000-0001-6258-6607</orcidid><orcidid>https://orcid.org/0000-0002-9154-5860</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2193-8237
ispartof Pain and Therapy, 2021-12, Vol.10 (2), p.1171-1188
issn 2193-8237
2193-651X
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8586321
source DOAJ Directory of Open Access Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central; Springer Nature OA Free Journals
subjects Cancer pain
Cancer patients
Diagnosis
Evaluation
Health surveys
Internal Medicine
Medicine
Medicine & Public Health
Original Research
Pain Medicine
Surveys
title The Italian Questionnaire for Cancer Breakthrough Pain Diagnosis, a Multicenter Validation Study
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-03T02%3A42%3A21IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20Italian%20Questionnaire%20for%20Cancer%20Breakthrough%20Pain%20Diagnosis,%20a%20Multicenter%20Validation%20Study&rft.jtitle=Pain%20and%20Therapy&rft.au=Samolsky%20Dekel,%20Boaz%20Gedaliahu&rft.date=2021-12-01&rft.volume=10&rft.issue=2&rft.spage=1171&rft.epage=1188&rft.pages=1171-1188&rft.issn=2193-8237&rft.eissn=2193-651X&rft_id=info:doi/10.1007/s40122-021-00274-9&rft_dat=%3Cgale_pubme%3EA682168763%3C/gale_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2538047535&rft_id=info:pmid/34091817&rft_galeid=A682168763&rfr_iscdi=true